FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891812864> ?p ?o ?g. }

• W2891812864 endingPage "38" @default.
• W2891812864 startingPage "33" @default.
• W2891812864 abstract "Chronic obstructive pulmonary disease (COPD) causes significant mortality in Japan. GFF MDI is a long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a metered dose inhaler (MDI) using co-suspension delivery technology, for the long-term maintenance treatment of COPD.This randomized, Phase I, single-dose, four-treatment, four-period, crossover study (NCT02196714) examined the pharmacokinetic (PK) and safety profile of two doses of GFF MDI (28.8 μg/10 μg and 14.4 μg/10 μg) and two doses of GP MDI (28.8 μg and 14.4 μg), both formulated using co-suspension delivery technology, in healthy Japanese subjects (18-45 years of age). PK parameters included area under the curve (AUC) from 0 to 12 h (AUC0-12), AUC from 0 to the time of the last measurable plasma concentration, maximum observed plasma concentration (Cmax), and time to Cmax. Safety was monitored throughout the study.Plasma GP profiles were comparable between GFF MDI and GP MDI formulations containing the same GP dose. Increases in GP AUC0-12 and Cmax were generally dose proportional from 14.4 to 28.8 μg after administration of either formulation.The addition of FF 10 μg to GP MDI 28.8 μg or 14.4 μg in a fixed-dose combination did not appreciably alter the PK of GP, nor did an increase in GP dose from 14.4 μg to 28.8 μg in a fixed-dose combination with FF 10 μg appreciably alter the PK of formoterol. Both formulations of GFF MDI and GP MDI were well tolerated in healthy Japanese subjects. Data from this study support further evaluation of GFF MDI in Japanese patients with COPD." @default.
• W2891812864 created "2018-09-27" @default.
• W2891812864 creator A5002361764 @default.
• W2891812864 creator A5002603430 @default.
• W2891812864 creator A5011502862 @default.
• W2891812864 creator A5077419098 @default.
• W2891812864 creator A5077936927 @default.
• W2891812864 creator A5081131385 @default.
• W2891812864 date "2018-12-01" @default.
• W2891812864 modified "2023-09-24" @default.
• W2891812864 title "Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects" @default.
• W2891812864 cites W1890874870 @default.
• W2891812864 cites W1905422379 @default.
• W2891812864 cites W1950043623 @default.
• W2891812864 cites W1963856068 @default.
• W2891812864 cites W1980858883 @default.
• W2891812864 cites W2006528231 @default.
• W2891812864 cites W2030987445 @default.
• W2891812864 cites W2039237831 @default.
• W2891812864 cites W2054393857 @default.
• W2891812864 cites W2055457865 @default.
• W2891812864 cites W2056040906 @default.
• W2891812864 cites W2062720719 @default.
• W2891812864 cites W2069155889 @default.
• W2891812864 cites W2069984535 @default.
• W2891812864 cites W2119767177 @default.
• W2891812864 cites W2128643475 @default.
• W2891812864 cites W2142449488 @default.
• W2891812864 cites W2317895461 @default.
• W2891812864 cites W2337977096 @default.
• W2891812864 cites W2558903543 @default.
• W2891812864 cites W2568255753 @default.
• W2891812864 cites W2591678263 @default.
• W2891812864 cites W2746473595 @default.
• W2891812864 cites W2746644590 @default.
• W2891812864 cites W2753051611 @default.
• W2891812864 cites W2761239349 @default.
• W2891812864 cites W2794357789 @default.
• W2891812864 cites W2794709253 @default.
• W2891812864 cites W2797158782 @default.
• W2891812864 cites W2885109827 @default.
• W2891812864 cites W2892705619 @default.
• W2891812864 doi "https://doi.org/10.1016/j.pupt.2018.09.005" @default.
• W2891812864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30218695" @default.
• W2891812864 hasPublicationYear "2018" @default.
• W2891812864 type Work @default.
• W2891812864 sameAs 2891812864 @default.
• W2891812864 citedByCount "7" @default.
• W2891812864 countsByYear W28918128642019 @default.
• W2891812864 countsByYear W28918128642020 @default.
• W2891812864 countsByYear W28918128642021 @default.
• W2891812864 countsByYear W28918128642022 @default.
• W2891812864 crossrefType "journal-article" @default.
• W2891812864 hasAuthorship W2891812864A5002361764 @default.
• W2891812864 hasAuthorship W2891812864A5002603430 @default.
• W2891812864 hasAuthorship W2891812864A5011502862 @default.
• W2891812864 hasAuthorship W2891812864A5077419098 @default.
• W2891812864 hasAuthorship W2891812864A5077936927 @default.
• W2891812864 hasAuthorship W2891812864A5081131385 @default.
• W2891812864 hasBestOaLocation W28918128641 @default.
• W2891812864 hasConcept C112705442 @default.
• W2891812864 hasConcept C126322002 @default.
• W2891812864 hasConcept C142724271 @default.
• W2891812864 hasConcept C204787440 @default.
• W2891812864 hasConcept C22979827 @default.
• W2891812864 hasConcept C27081682 @default.
• W2891812864 hasConcept C2776042228 @default.
• W2891812864 hasConcept C2776136866 @default.
• W2891812864 hasConcept C2776623344 @default.
• W2891812864 hasConcept C2776780178 @default.
• W2891812864 hasConcept C2776954882 @default.
• W2891812864 hasConcept C2779871671 @default.
• W2891812864 hasConcept C2780261241 @default.
• W2891812864 hasConcept C2780667556 @default.
• W2891812864 hasConcept C2781018748 @default.
• W2891812864 hasConcept C2909086917 @default.
• W2891812864 hasConcept C42219234 @default.
• W2891812864 hasConcept C71924100 @default.
• W2891812864 hasConcept C76318530 @default.
• W2891812864 hasConcept C87813604 @default.
• W2891812864 hasConcept C98274493 @default.
• W2891812864 hasConceptScore W2891812864C112705442 @default.
• W2891812864 hasConceptScore W2891812864C126322002 @default.
• W2891812864 hasConceptScore W2891812864C142724271 @default.
• W2891812864 hasConceptScore W2891812864C204787440 @default.
• W2891812864 hasConceptScore W2891812864C22979827 @default.
• W2891812864 hasConceptScore W2891812864C27081682 @default.
• W2891812864 hasConceptScore W2891812864C2776042228 @default.
• W2891812864 hasConceptScore W2891812864C2776136866 @default.
• W2891812864 hasConceptScore W2891812864C2776623344 @default.
• W2891812864 hasConceptScore W2891812864C2776780178 @default.
• W2891812864 hasConceptScore W2891812864C2776954882 @default.
• W2891812864 hasConceptScore W2891812864C2779871671 @default.
• W2891812864 hasConceptScore W2891812864C2780261241 @default.
• W2891812864 hasConceptScore W2891812864C2780667556 @default.
• W2891812864 hasConceptScore W2891812864C2781018748 @default.
• W2891812864 hasConceptScore W2891812864C2909086917 @default.
• W2891812864 hasConceptScore W2891812864C42219234 @default.

• next